PsyCap Recap: 3 Key Takeaways from the Lobe Sciences Psychedelic Capital Presentation

The human brain is the most complex organ in the human body and the focus of many researchers amidst this modern psychedelic renaissance. Currently, research into brain injuries has failed to produce efficacious treatments and clinical outcomes for brain injuries in the US are poor. One company looking to advance research into this space is Lobe Sciences. Their dedicated and highly experienced team of pioneering scientists, engineers, and physicians, are committed to investigating and developing treatments for brain injury and various brain disorders. Here are three key takeaways from their February 2021 Psychedelic Capital presentation.

Don’t miss the next Psychedelic Capital event which will feature renowned thought leaders in the psychedelic industry, including MAPS founder, Rick Doblin. You can grab your free ticket here. Use Coupon Code PSYCAP on the checkout.

Lobe Sciences PsyCap presentation Feb 2021

Key Takeaway #1: The Lobe Leadership Team Brings Robust Experience & Ingenuity

When it comes to developing new psychedelic drugs and providing new pathways to treat brain injury and brain disorders, the Lobe Sciences team could not be better prepared. Their Chief Science Officer, Maghsoud Dariani, has had notable success in seeing the ADHD drugs Focalin and Adderall through the lengthy drug development pipeline. Their CEO and Director, Philip Young, has served in executive positions in public companies for the past two decades where has created significant shareholder value, built integrated scientific, manufacturing and commercial operations, directed successful M&A transactions, and was responsible for generating more than $900M through acquisitions and equity financings. They are also collaborating with one of the best engineering teams in America. Between Lobe’s highly experienced executive team and expert advisors, they are undoubtedly equipped to face the challenges ahead and successfully develop the next generation of psychedelic drugs that treat brain injury and general disorders.

Lobe Sciences PsyCap presentation Feb 2021

Key Takeaway #2: Lobe is Developing a Proprietary & Patentable Nasal Device to Deliver a Microdose of Psilocybin

The Lobe Sciences team is currently working to create a proprietary nasal device that will deliver a microdose of psilocybin in addition to NAC (N-acetyl-cysteine) for the treatment of mild TBI (traumatic brain injury) and subsequent PTSD (posttraumatic stress disorder). The spray will deliver the medication to the upper part of your sinus, where the olfactory bulb is located, offering the medication easy access to the brain. Furthermore, this allows for the ability to use lower concentrations because the first-pass metabolism is being avoided. The addition of NAC increases levels of glutathione, a potent antioxidant and anti-inflammatory molecule that protects cells from oxidative stress and damage from reactive oxygen species (ROS). Combined, the Lobe Sciences team feels confident that their product is novel and patentable, hence, giving them a significant market advantage. Lobe Sciences believes the ROA (route of administration) utilized in the spray with the precise microdose of psilocybin delivered will eliminate the need for an entire day session with a therapist and allow patients to self-administer their medication. Essentially, the Lobe team wants to treat patients where they are: their home and their offices. Their proprietary nasal spray currently in development is poised to help them meet that goal.

Lobe Sciences PsyCap presentation Feb 2021

Key Takeaway #3: Lobe Sciences is Conducting Well-Designed Studies & Taking a Multidisciplinary Approach

Their highly experienced Lobe Sciences R&D team is conducting well-crafted preclinical research to help guide the development of their novel therapeutics. Currently, the Lobe team is utilizing two well-established rodent models and each animal study has multiple arms (sham, placebo arm, combination, and individual component). The goal is to show the superiority of their combination drug therapeutic over other available treatments. In addition to conducting comprehensive preclinical research, it is also worth noting the Lobe team’s multidisciplinary approach towards psychedelic therapeutics for brain injuries and disorders. Indeed, their team of doctors, scientists, and psychiatrists have a versatile set of experiences, skills, and insight that is sure to be incredibly valuable to their strategy moving forward.

Lobe Sciences PsyCap presentation Feb 2021

Looking Ahead for Lobe Sciences

Between the innovative development of their combination psilocybin microdose nasal spray and their uniquely experienced leadership team, Lobe Sciences is well-positioned to succeed. Their multidisciplinary approach towards psychedelic therapeutics has helped craft their innovative preclinical trials, with ample

Microdose Psychedelic Insights

Microdose Psychedelic Insights

Your Guide to the Business of Psychedelics. Our mission is to shift the world's perception of psychedelic medicine.